Please use this identifier to cite or link to this item:
|Title:||Cystargamide B, a cyclic lipodepsipeptide with protease inhibitory activity from Streptomyces sp.|
Toyama Prefectural University
National Institute of Infectious Diseases
National Institutes of Health, Bethesda
|Keywords:||Pharmacology, Toxicology and Pharmaceutics|
|Citation:||Journal of Antibiotics. Vol.71, No.7 (2018), 662-666|
|Abstract:||© 2018 The Author(s) under exclusive licence to the Japan Antibiotics Research Association. We identified a new cyclic lipodepsipeptide, cystargamide B (1), from the mycelial extract of a Kaempferia galanga rhizome-derived actinomycete strain, Streptomyces sp. PB013. The planar structure was elucidated based on high resolution fast-atom bombardment mass spectrometry (HRFABMS) spectroscopy and one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR) spectroscopic data. The absolute configurations of the constituent amino acids were determined using advanced Marfey's method. Cystargamide B (1) includes rare structural units: a 5-hydroxytryptophan residue and a 2,3-epoxy fatty acid side chain. Notably, cystargamide B (1) inhibited the protease activity of the NS2B/NS3 complex from dengue virus.|
|Appears in Collections:||Scopus 2018|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.